Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout ...
Standard BioTools (LAB) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago. These figures are adjusted ...
Hosted on MSN
Standard BioTools outlines $165M-$175M revenue target for FY2025 while driving proteomics partnerships
CEO Michael Egholm highlighted that Standard BioTools delivered Q1 2025 revenues of $40.8 million, aligned with their plan despite a challenging operating backdrop. He emphasized improvements in ...
Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business. The deal with ...
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results